Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NovaBay Pharmaceuticals has received a US Patent covering the use of NeutroPhase in wound care applications, under conditions that the company believes are optimal for efficacy and stability.
Subscribe to our email newsletter
NeutroPhase is a dilute solution of hypochlorous acid, which is rapid-acting in saline with broad-spectrum antimicrobial properties. In September 2007, NovaBay received 510(K) approval from the US Food and Drug Administration to market NeutroPhase, also known as NVC-101.
Jack O’Reilly, NovaBay’s senior vice president of corporate and business development, said: “Our intellectual property continues to develop because of our scientists’s deepening understanding of NeutroPhase and our Aganocide anti-microbial compounds.”